- Home
- PETS vs SPRO Comparison
PETS vs SPRO Comparison
Compare PETS & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- SPRO
- Stock Information
- Founded
- PETS 1996
- SPRO 2013
- Country
- PETS United States
- SPRO United States
- Employees
- PETS N/A
- SPRO N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- SPRO Health Care
- Exchange
- PETS Nasdaq
- SPRO Nasdaq
- Market Cap
- PETS 82.0M
- SPRO 66.5M
- IPO Year
- PETS N/A
- SPRO 2017
- Fundamental
- Price
- PETS $3.98
- SPRO $1.27
- Analyst Decision
- PETS Sell
- SPRO Strong Buy
- Analyst Count
- PETS 2
- SPRO 3
- Target Price
- PETS $3.50
- SPRO $7.00
- AVG Volume (30 Days)
- PETS 174.8K
- SPRO 139.0K
- Earning Date
- PETS 10-28-2024
- SPRO 11-11-2024
- Dividend Yield
- PETS 28.95%
- SPRO N/A
- EPS Growth
- PETS N/A
- SPRO N/A
- EPS
- PETS N/A
- SPRO 0.33
- Revenue
- PETS $270,772,000.00
- SPRO $118,459,000.00
- Revenue This Year
- PETS N/A
- SPRO N/A
- Revenue Next Year
- PETS $3.27
- SPRO N/A
- P/E Ratio
- PETS N/A
- SPRO $3.90
- Revenue Growth
- PETS 2.26
- SPRO 118.43
- 52 Week Low
- PETS $2.90
- SPRO $0.99
- 52 Week High
- PETS $10.53
- SPRO $1.89
- Technical
- Relative Strength Index (RSI)
- PETS 54.93
- SPRO 47.45
- Support Level
- PETS $3.89
- SPRO $1.20
- Resistance Level
- PETS $4.22
- SPRO $1.34
- Average True Range (ATR)
- PETS 0.20
- SPRO 0.05
- MACD
- PETS -0.02
- SPRO 0.00
- Stochastic Oscillator
- PETS 47.37
- SPRO 53.33
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.